# Establish a Public Private Partnership for COVID19 Research

> **NIH NIH OT2** · FOUNDATION FOR THE NIH · 2020 · $1,796,424

## Abstract

The Foundation for the National Institutes of Health (FNIH) (www.fnih.org) was chartered by the Congress of the
United States in 1990 as a not-for-profit 501(c)(3) charitable organization and has been working to facilitate
groundbreaking research at the National Institutes of Health (NIH) and worldwide since 1996, creating and
managing numerous biomedical public-private research partnerships that support the NIH’s mission. The FNIH
therefore has extensive experience working with both NIH and the biopharmaceutical industry and deep familiarity
with NIH’s people, science, practices, and policies.
The FNIH has been asked by Dr. Francis S. Collins, Director of the NIH, to assist the agency in its response to the
COVID-19 crisis. The aim of this collaboration is to accelerate NIH research urgently required to respond to this
public health threat and to save lives by leveraging private-sector scientific expertise, in-kind assets and financial
resources to augment federal efforts.
Dr. Collins’ request that the FNIH help create a COVID-19 public-private partnership (PPP) to accelerate the
development of therapeutics and vaccines under the Accelerating Medicines Partnership (AMP) is consistent with
the FNIH’s own mission and the Congressional statute by which the FNIH was established to support the NIH in
its mission and to advance collaboration with biomedical researchers from universities, industry, nonprofit
organizations and other federal agencies, including the US Food and Drug Administration (FDA).
AMP is a nimble and powerful public-private partnership that includes the NIH, FNIH, FDA and multiple
biopharmaceutical companies and not-for-profit organizations. Managed by the FNIH, AMP programs bring
together the resources of the NIH and industry to improve our understanding of disease pathways and facilitate
better selection of targets for treatment. Multimillion dollar collaborations supported by the private sector through
the FNIH have been established in four major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid
Arthritis (RA)/Lupus and Parkinson's disease. The FNIH is also preparing to launch an AMP in Schizophrenia in
partnership with the National Institute on Mental Health (NIMH).
The overarching goal of the FNIH in this new AMP is to support the NIH in designing and implementing a strategic
and coordinated cross-sector approach to end the current COVID-19 pandemic and to manage future such threats.
This PPP is now known as ACTIV, the Accelerated COVID-19 Therapeutic Intervention and Vaccine partnership.
Notably, most AMP projects start with a Design Phase that takes approximately 9 months to complete in which the
FNIH identifies key partners, establishes scientific working and sub-groups, puts in place governance structures,
executes contracts and agreements, deploys and trains appropriate staff, and identifies potential sources of funding.
The result of the Design Phase is a detailed scientific and business plan for the PPP, w...

## Key facts

- **NIH application ID:** 10149062
- **Project number:** 1OT2OD030195-01
- **Recipient organization:** FOUNDATION FOR THE NIH
- **Principal Investigator:** Stacey Adam
- **Activity code:** OT2 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,796,424
- **Award type:** 1
- **Project period:** 2020-05-02 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10149062

## Citation

> US National Institutes of Health, RePORTER application 10149062, Establish a Public Private Partnership for COVID19 Research (1OT2OD030195-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10149062. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*